Enzo Biochem (NYSE: ENZ) and NeoGenomics (NASDAQ:NEO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitabiliy and risk.

Volatility and Risk

Enzo Biochem has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.


This table compares Enzo Biochem and NeoGenomics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enzo Biochem 31.57% -5.13% -4.17%
NeoGenomics -4.92% 5.85% 3.10%

Earnings and Valuation

This table compares Enzo Biochem and NeoGenomics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Enzo Biochem $106.24 million 4.82 -$4.59 million $0.72 15.33
NeoGenomics $246.06 million 2.89 $27.30 million ($0.36) -24.89

NeoGenomics has higher revenue and earnings than Enzo Biochem. NeoGenomics is trading at a lower price-to-earnings ratio than Enzo Biochem, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

61.2% of Enzo Biochem shares are held by institutional investors. Comparatively, 77.5% of NeoGenomics shares are held by institutional investors. 9.5% of Enzo Biochem shares are held by company insiders. Comparatively, 12.2% of NeoGenomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Enzo Biochem and NeoGenomics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enzo Biochem 0 0 0 0 N/A
NeoGenomics 1 0 6 0 2.71

NeoGenomics has a consensus target price of $11.00, indicating a potential upside of 22.77%. Given NeoGenomics’ higher probable upside, analysts clearly believe NeoGenomics is more favorable than Enzo Biochem.


NeoGenomics beats Enzo Biochem on 9 of the 12 factors compared between the two stocks.

About Enzo Biochem

Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women’s health infectious agents, as well as for use in the identification of pathogens for other markets.

About NeoGenomics

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients’ oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.